SPVN06
SPVN06 is an experimental gene therapy for rod-cone dystrophy developed by SparingVision.[1][2]
References[edit]
- ^ Lorget, Florence; Marie, Melanie; Khabou, Hanen; Simon, Cardillia; Nuno, Didier; Vanlandingham, Phillip; Quiambao, Alain; Farjo, Rafal; Dalkara, Deniz; Sahel, Jose Alain; Leveillard, Thierry D (2022-06-01). "SPVN06, a novel mutation-independent AAV-based gene therapy, dramatically reduces vision loss in the rd10 mouse model of rod-cone dystrophy". Investigative Ophthalmology & Visual Science. 63 (7). The Association for Research in Vision and Ophthalmology: 56 – A0029–56 – A0029. ISSN 1552-5783. Retrieved 2023-12-05.
- ^ Novack, Gary D. (January 2021). "Repurposing medications". The Ocular Surface. 19: 336–340. doi:10.1016/j.jtos.2020.11.012. ISSN 1542-0124. PMC 7690306. PMID 33249292.